Diagnostics and Treatment of Malignant Ovarian Tumors
DOI:
https://doi.org/10.26332/1xsrvv94Keywords:
Ovarian Neoplasms, Chemotherapy, Adjuvant, Ultrasonography, Fertility Preservation, RecurrenceAbstract
Malignant ovarian tumors represent a heterogeneous group of neoplasms and a significant clinical challenge. Due to non-specific symptoms in the early stages, they are often diagnosed late, resulting in poor prognosis. Diagnostic evaluation involves a combination of medical history, physical examination, tumor marker assessment, and imaging techniques. Transvaginal ultrasound is the first-line imaging modality, followed by CT, MRI, or PET/CT as needed. Accurate staging is essential for choosing the optimal therapeutic approach. Standard treatment consists of surgery and platinum-based chemotherapy, with PARP inhibitors and anti-angiogenic therapies used in maintenance. In selected young patients, fertility-sparing surgery may be considered. The management of recurrent disease is individualized based on patient characteristics, tumor biology and previous response to therapy.
References
1. Reid BM, Permuth JB, Sellers TA. Epidemiology of ovarian cancer: a review. Cancer Biol Med. 2017;14(1):9–32. doi:10.20892/j.issn.2095-3941.2016.0084.
2. Hoffman BL, Schorge JO, Bradshaw KD, Halvorson LM, Schafer JI, Corton MM. Williams Gynecology. 3rd ed. Zagreb: Medicinska naklada; 2021. p. 735–55. [in Croatian]
3. Dochez V, Caillon H, Vaucel E, Dimet J, Winer N, Ducarme G. Biomarkers and algorithms for diagnosis of ovarian cancer: CA125, HE4, RMI and ROMA, a review. J Ovarian Res. 2019;12:28. doi:10.1186/s13048-019-0503-7.
4. Matsas A, Stefanoudakis D, Troupis T, Kontzoglou K, Eleftheriades M, Christopoulos P, Kalampokas T, Papadias K, Tsaroucha AK. Tumor markers and their diagnostic significance in ovarian cancer. Life (Basel). 2023;13(8):1689. doi:10.3390/life13081689.
5. Sayasneh A, Ekechi C, Ferrara L, Kaijser J, Stalder C, Sur S, Bignardi T, Timmerman D, Bourne T. The characteristic ultrasound features of specific types of ovarian pathology: a review. Int J Oncol. 2015;46(2):445–58. doi:10.3892/ijo.2014.2764.
6. González-Martín A, Harter P, Leary A, Lorusso D, Miller RE, Pothuri B, Moore KN, Oaknin A, Ray-Coquard I, Colombo N. Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(10):833–48. doi:10.1016/j.annonc.2023.07.011.
7. Yeung TL, Leung CS, Yip KP, Au Yeung CL, Wong STC, Mok SC. Cellular and molecular processes in ovarian cancer metastasis: a review in the theme: cell and molecular processes in cancer metastasis. Am J Physiol Cell Physiol. 2015;309(7):C444–56. doi:10.1152/ajpcell.00188.2015.
8. Kleppe M, Wang T, Van Gorp T, Slangen BFM, Kruse AJ, Kruitwagen RFPM. Lymph node metastasis in stages I and II ovarian cancer: a review. Gynecol Oncol. 2011;123(3):610–14. doi:10.1016/j.ygyno.2011.09.013.
9. Petrić Miše B, Matković V, Belac Lovasić I, Fröbe A, Boraska-Jelavić T, Katić K, Gračan S, Novaković D, Grahovac B. Kliničke smjernice za dijagnozu, liječenje i praćenje bolesnica oboljelih od raka jajnika, jajovoda i potrbušnice. Liječ Vjesn. 2021;143(11–12):416–28. doi:10.26800/LV-143-11-12-3. [in Croatian]
10. Faubion SS, MacLaughlin KL, Long ME, Pruthi S, Casey PM. Surveillance and care of the gynecologic cancer survivor. J Womens Health (Larchmt). 2015;24(11):899–906. doi:10.1089/jwh.2014.5127.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Southeastern European Medical Journal
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
